Get the Stockscreener App
1.95
3.47%
-0.07
After Hours:
1.98
0.03
+1.54%
Palisade Bio Inc stock is traded at $1.95, with a volume of 2.33M.
It is down -3.47% in the last 24 hours and up +1.56% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$2.02
Open:
$2.04
24h Volume:
2.33M
Relative Volume:
0.63
Market Cap:
$338.87M
Revenue:
$250.00K
Net Income/Loss:
$-24.15M
P/E Ratio:
-1.83
EPS:
-1.0656
Net Cash Flow:
$-12.40M
1W Performance:
-1.02%
1M Performance:
+1.56%
6M Performance:
+2.09%
1Y Performance:
+75.68%
1-Day Range:
$1.895
$2.05
1-Week Range:
$1.875
$2.20
52-Week Range:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.95 | 338.87M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
TradingKey - TradingKey
Palisade Bio Inc. (PALI) Dips 3.5% as Shares Test Key Support at $1.85Reversal Setup Alerts - dars.gov.et
PALI|Palisade Bio Inc|Price:1.950|Chg%:-0.070 - TradingKey
Enterprise value to revenue forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis - Benzinga
PALI Initiates Coverage On by Oppenheimer -- Rating 'Outperform' - GuruFocus
Palisade Bio jumps following Oppenheimer outperform initiation (PALI:NASDAQ) - Seeking Alpha
Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target - marketscreener.com
Enterprise value to revenue forward of Palisade Bio, Inc. – LS:A4098S - TradingView
Insider Buying: Robert Baltera Acquires 45,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock By Investing.com - Investing.com India
Form 4 Palisade Bio Inc For: 10 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock - Investing.com UK
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - The Manila Times
Palisade Bio to present clinical updates at Lee... - Pluang
Palisade Bio leaders set to outline IBD drug plans at Boston forum - Stock Titan
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets - Seeking Alpha
Insider Buying: Robert Baltera Acquires 50,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com - Investing.com Nigeria
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
Palisade Bio CEO, CFO Finley sells $303k in stock By Investing.com - Investing.com South Africa
Palisade Bio chief medical officer Jones sells $106,535 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock By Investing.com - Investing.com Nigeria
Palisade Bio CEO, CFO Finley sells $303k in stock - Investing.com
Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys - Stock Titan
[Form 4] PALISADE BIO, INC. Insider Trading Activity - Stock Titan
Palisade Bio (PALI) CEO Finley sells shares to cover RSU tax - Stock Titan
Stifel Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Insider Spends US$59k Buying More Shares In Palisade Bio - simplywall.st
Palisade Bio Inc. (PALI) Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D FocusPre-Earnings Drift - dars.gov.et
Form 144 PALISADE BIO For: 7 July By Investing.com - Investing.com Nigeria
[144] PALISADE BIO, INC. SEC Filing - Stock Titan
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock - Investing.com
Form 4 Palisade Bio Inc For: 6 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock By Investing.com - Investing.com South Africa
Palisade Bio (PALI) director adds 30,000 shares in open-market buys - Stock Titan
Price to book forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Should I Buy PALI? PALI 2026 AnalysisIntellectia AI™ - Intellectia AI
Analysts’ Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT) - The Globe and Mail
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):